Skip to main content
PMC home page
Cytotechnology logoLink to Cytotechnology
. 1998 Nov;28(1-3):81–89. doi: 10.1023/A:1008021428969

A high-yielding serum-free, suspension cell culture process to manufacture recombinant adenoviral vectors for gene therapy

G Schoofs 1, T J Monica 1, J Ayala 1, J Horwitz 1, T Montgomery 1, G Roth 1, F J Castillo 1
PMCID: PMC3449833  PMID: 19003410

Abstract

We have developed an efficient, reproducible, and scaleable cell culture process for a recombinant adenoviral vector expressing therapeutic transgenes for clinical trials. HEK 293 cells – which support the propagation of E1 deficient adenovirus – were first adapted to serum free media and suspension growth. Subsequent studies focused on the infection, virus production and harvest from suspension culture bioreactors. Future studies are planned to address the kinetics of adenovirus production in HEK 293 as well as in other cell lines.

Keywords: adenovirus, HEK 293, perfusion, serum free media, suspension perfusion

Full Text

The Full Text of this article is available as a PDF (484.9 KB).

References

  1. Crystal RG. Transfer of genes to humans: early lessons and obstacles to success. Science. 1995;270:404–410. doi: 10.1126/science.270.5235.404. [DOI] [PubMed] [Google Scholar]
  2. Garnier A, Cote J, Nadeau I, Kamen A, Massie B. Scale-up of the adenovirus expression system for the production of recombinant protein in human 293S cells. Cytotechnology. 1994;15:145–155. doi: 10.1007/BF00762389. [DOI] [PubMed] [Google Scholar]
  3. Graham FL, Prevec L. Manipulation of adenovirus vectors. In: Murray EJ, editor. Methods in Molecular Biology. Clifton, NJ: The Humana Press; 1991. pp. 109–128. [DOI] [PubMed] [Google Scholar]
  4. Green M, Wold WSM. Human adenoviruses: Growth, purification, and transfection assay. Meth Enzym. 1979;58:425–435. doi: 10.1016/S0076-6879(79)58157-9. [DOI] [PubMed] [Google Scholar]
  5. Hehir K, Keegan J, Martin J, Pratt D, Auger C, Davis M, Everton M, Narayana R and Karey K (1998) Production issues for adenoviral gene therapy vectors. Presented at Cell Culture Engineering VI, February 7-12, 1998, San Diego, CA.
  6. Marcel T, Grausz JD. The TMC worldwide gene therapy enrollment report, end 1996. Human Gene Therapy. 1997;8:775–800. doi: 10.1089/hum.1997.8.6-775. [DOI] [PubMed] [Google Scholar]
  7. Nadeau I, Garnier A, Cote J, Massie B, Chavarie C, Kamen A. Improvement of recombinant protein production with the human adenovirus/293S expression system using fed-batch strategies. Biotech Bioeng. 1996;51:613–623. doi: 10.1002/(SICI)1097-0290(19960920)51:6<613::AID-BIT1>3.0.CO;2-K. [DOI] [PubMed] [Google Scholar]
  8. Nielsen LK, Smyth GK, Greenfield PF. Accuracy of the endpoint assay for virus titration. Cytotechnology. 1992;8:231–236. doi: 10.1007/BF02522040. [DOI] [PubMed] [Google Scholar]
  9. Roth G, Smith C, Schoofs GM, Montgomery TJ, Ayala JL, Horwitz JI. Using an external vortex flow filtration device for perfusion cell culture. BioPharm. 1997;10:30–35. [Google Scholar]
  10. Shabram PW, Giroux DD, Goudreau AM, Gregory RJ, Horn MT, Huyghe BG, Liu X, Nunnally MH, Sugarman BJ, Sutjipto S. Analytical anion-exchange HPLC of recombinant type-5 adenoviral particles. Human Gene Therapy. 1997;8:453–465. doi: 10.1089/hum.1997.8.4-453. [DOI] [PubMed] [Google Scholar]

Articles from Cytotechnology are provided here courtesy of Springer Science+Business Media B.V.

RESOURCES